1 1

Anti-Human CD20 Monoclonal Antibody (Ofatumumab)

Anti-Human CD20 Monoclonal Antibody (Ofatumumab)

Catalog Number: UA016165 Brand: UA BIOSCIENCE
Share:
Price:
$90 USD
$90 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Human
Synonyms Ofatumumab
Concentration 2mg/mL
Expression System HEK293
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, containing no preservative
Stability & Storage

2 to 8 °C for 2 weeks under sterile conditions;

-20 °C for 3 months under sterile conditions;

-80 °C for 24 months under sterile conditions.

Please avoid repeated freeze-thaw cycles.
Reference

1. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.
2. Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022 Sep;28(10):1562-1575.

Background

Ofatumumab is a fully humanized monoclonal antibody that targets the CD20 molecule on the surface of B cells. Its core mechanism of action involves binding to the CD20 protein, thereby triggering multiple effector functions—including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis—to efficiently deplete CD20-positive B lymphocytes. Clinically, ofatumumab has a dual application: the intravenous formulation (Arzerra®) is indicated for the treatment of chronic lymphocytic leukemia, while the subcutaneous formulation (Kesimpta®) has been approved for the management of adult relapsing forms of multiple sclerosis, effectively reducing relapse rates and delaying disability progression. Notably, its convenient once‑monthly, at‑home self‑administration regimen offers significant advantages in facilitating long‑term disease management for patients with multiple sclerosis.

Picture

ELISA

Immobilized CD20 Flag&His Tag Protein, Human (Detergent) at 5.0μg/mL (100μL/well) can bind Anti-Human CD20 Monoclonal Antibody (Ofatumumab) (Cat. No. UA016165) with EC50 of 0.76-1.64 ng/mL.